Skip to content

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07018986
Acronym
MIND-BC
Enrollment
200
Registered
2025-06-13
Start date
2025-07-09
Completion date
2030-03-01
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This fully, powered efficacy RCT, the MIND diet for Breast Cancer Cognition (MIND-BC), will evaluate the MIND diet in a rigorous, highly controlled academic cancer center. We will recruit breast cancer survivors reporting CRCI with a MIND diet score \< 8, based on a previously devised 14-item diet questionnaire designed to detect inadequate diet with respect to brain health (scores range from 0 to 14, with lower scores indicating a less adequate diet).14 Breast cancer survivors will have recently completed adjuvant treatment (i.e., 6 months to three years previously), to ensure that perceived cognitive impairment is likely chronic and due to cancer. To achieve maximal effect, the study consists of two 12-week phases 1) intervention phase, 2) maintenance phase.

Interventions

a combination of the Mediterranean and DASH diets emphasizing consumption of high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat.

Check-in sessions for the usual diet arm will focus on general health (e.g., healthy hair, skin, eyesight). None of the topics will include dietary information for the usual diet arm.

Sponsors

H. Lee Moffitt Cancer Center and Research Institute
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Previously diagnosed with stage I-III breast cancer. * Able to speak and read English. * Able to consume foods orally. * \>18 years of age. * Able to provide informed consent. * Have no documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., schizophrenia). * Report 'somewhat' to 'very much' cognitive impairment in the past week (i.e., a score ≥ 2 on a 0-4 scale) that they attribute to cancer or its treatment. * Report a MIND diet score \< 10 (range 0 to 14, higher score equates to higher diet quality). * Willing to consume the MIND diet. * Completed adjuvant treatment 6 months to three years previously.

Exclusion criteria

* Not meeting all of the inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of the MIND diet: Self-reported cognitionAt 12 weeks and 3 monthsThe Functional Assessment of Cancer Therapy - General (FACT-G) will be used to determine self-reported cognition.

Secondary

MeasureTime frameDescription
Efficacy of the MIND diet: Quality of life (QOL) and moodAt 12 weeks and 3 monthsThe European Organization for Research and Treatment of Cancer (EORTC) Quality of Life of Cancer Patients Questionnaire will be used to determine QOL and mood.
Efficacy of the MIND diet: FatigueAt 12 weeks and 3 monthsThe Functional Assessment of Chronic Illness Fatigue Subscale (FACIT Fatigue) will be used to determine fatigue.
Efficacy of the MIND diet: Objective cognitionAt Baseline, 12 weeks, and 3 monthsNeuropsychological tests (i.e., best objective performance) will be administered via the CANTAB Connect (Cambridge Cognition, Cambridge, UK) that contains a well-validated battery of tests based in neuropsychology and neuroscience administered in a semi-automated manner via the web that is automatically scored upon completion. EMA Participants will complete 3 prompted surveys and sets of EMA cognitive tasks throughout the day as well as an end of day survey each day for 7 days at baseline, 12 weeks, and 3 month follow-up including symbol search, dot memory test, shopping list associate test. All scores will be correlated to determine objective cognition.

Countries

United States

Contacts

CONTACTCrystal Bryant
Crystal.Bryant@moffitt.org813-745-2168
PRINCIPAL_INVESTIGATORSylvia Crowder

Moffitt Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026